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Abstract: Ovarian cancer is a highly heterogeneous disease and its formation is affected by many
epidemiological factors. It has typical lack of early signs and symptoms, and almost 70% of ovarian
cancers are diagnosed in advanced stages. Robust, early and non-invasive ovarian cancer diagnosis
will certainly be beneficial. Herein we analysed the regulatory sequence methylation profiles of the
RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes by pyrosequencing in healthy, benign and
malignant ovarian tissues, and corresponding plasma samples. We recorded statistically significant
higher methylation levels (p < 0.05) in the CDH1 and PAX1 genes in malignant tissues than in controls
(39.06 ± 18.78 versus 24.22 ± 6.93; 13.55 ± 10.65 versus 5.73 ± 2.19). Higher values in the CDH1 gene
were also found in plasma samples (22.25 ± 14.13 versus 46.42 ± 20.91). A similar methylation pattern
with positive correlation between plasma and benign lesions was noted in the CDH1 gene (r = 0.886,
p = 0.019) and malignant lesions in the PAX1 gene (r = 0.771, p < 0.001). The random forest algorithm
combining methylation indices of all four genes and age determined 0.932 AUC (area under the
receiver operating characteristic (ROC) curve) prediction power in the model classifying malignant
lesions and controls. Our study results indicate the effects of methylation changes in ovarian cancer
development and suggest that the CDH1 gene is a potential candidate for non-invasive diagnosis of
ovarian cancer.
Keywords: liquid biopsy; pyrosequencing; ovarian cancer; CDH1; PTEN; PAX1; RASSF1; cfDNA
1. Introduction
Ovarian cancer (OC) is one of the most lethal gynaecological cancerous diseases and the fifth leading
cause of cancer-related death in women. Although it is globally diagnosed in almost 240,000 women
annually and responsible for over 150,000 deaths each year [1], the incidence varies regionally and
it is generally higher in both developed countries and caucasian women. The following OC rates in
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100,000 women have been established: (1) Eastern Europe has 11.4 women diagnosed with OC in
every 100,000, (2) the Central Europe and North America have over 8, (3) Central and South America
have up to 6 and (4) the lowest rates are observed in Asia and Africa, at less than 3, usually [1,2]. It is
also important that OC incidence has been slightly decreasing in developed countries since 1990 but
increasing in developing countries [3–5]. OC is also very heterogeneous, with a variety of benign,
borderline and malignant variants, almost all of which arise from transformation of epithelial, stromal
and germ cell types [6]. Of these, the most common malignant neoplasms have their origin in the
epithelium in up to 90% OC while the germ cell type are very rare with only 2–3% [6].
Ovarian tumours (OT) were traditionally divided into five groups: Serous, mucinous,
endometrioid, clear cell and transitional [7]. However, each of those also comprised variable forms
of benign, borderline and malignant lesions, with a total of over 40 tumour types. This classification
primarily focused on the ovarian mesothelial surface as the point of origin for epithelial OT [7], but the
more recent 2014 WHO classification, established in parallel with new FIGO staging implementation,
excluded transitional cell tumours, but added the new sero-mucinous tumour group [7]. This latest
classification is considered more consistent and it also comprises only 28 tumour types. While
Meinhold-Heerlein et al. [7] have compared the traditional and new classification in detail many
analyses have been based on older classification, and the results from those studies quoted herein
are in their original form. However, it is essential to remember that OC is a very variable group of
cancerous diseases and their formation is affected by many epidemiological factors [2]. It is especially
typical in its lack of early signs and symptoms, and almost 70% of these cancers are diagnosed in
advanced stages [8].
Diagnosed OC is primarily treated surgically with subsequent application of platine and taxane
based adjuvant chemotherapy [9], but the efficacy of surgical treatment followed by chemotherapy
rapidly decreases with the identified stage of the tumour [8]. The statistics for variable OC histotypes
highlight that only 20% of women in advanced stages have five-year survival after diagnosis, while 89%
diagnosed in stage I and 71% in stage II survive five years [8]. Moreover, OC metastases spread very
quickly using two strategies: (1) Transcoelomic passive dissemination of tumour cell spheroids in
the peritoneal cavity through ascites and (2) haematogenous metastasis of OC cells in the systemic
circulation followed by the preferred seeding of the omentum [10–12]. It is therefore essential to
use the robust, sensitive and non-invasive liquid biopsy (LB) approach for early OC diagnosis and
differentiation. This methodology overcomes the typical limitations of solid tumour biopsies, such as
invasiveness connected with unexpected complications during surgical procedures, difficulties in
operating on organs that lie deep within the body, false negativity from sampling bias and the
impossibility of repeating the same intervention [13]. Most importantly, solid biopsies provide no
possibility for early tumour diagnosis and differentiation; they give tumour information only at
particular points in time and they preclude monitoring the response to medication during treatment
and follow up. In contrast, these are all possible with the LB approaches focused on detection and
characterisation of abnormalities in circulating tumour cells (CTC), circulating tumour DNA (ctDNA),
circulating cell-free microRNAs (cfmiRNA) and released exosome vesicles [10].
This cross-sectional study focuses on epigenetic changes, particularly alterations in methylation
levels in primary tumours and the paired plasma samples. It then analyses the model’s predictive
power in distinguishing between diagnoses so that this can be used in clinically predicting the risk of
OC. For this purpose, four tumour-suppressor genes: Ras Association Domain Family Member 1 (RASSF1),
Paired Box 1 (PAX1), Cadherin 1 (CDH1) and Phosphatase and Tensin Homolog (PTEN) were analysed.
RASSF1 inactivation is connected with the development and progression of many cancer
types, and while this inactivation can be caused by deletions and point mutations, it most often
arises from methylation changes [14,15]. RASSF1 encodes a protein similar to the RAS effector
proteins [16] and this product regulates cell-cycle progression and apoptosis pathways, especially the
Ras/PI3K/AKT, Ras/RAF/MEK/ERK and Hippo apoptosis pathways [16]. It also regulates Bax-mediated
cell death [17], interacts with the XPA DNA repair gene [18] and inhibits accumulation of cyclin
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D1 [19]. In addition, it inhibits anaphase-promoting complex (APC) activity and mitotic progression
following interaction with CDC20 [20]. PTEN is a multifunctional tumour-suppressor gene encoding
phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, which de-phosphorylates phosphoinositide
substrates, and it is also an important regulator of insulin signalling, glucose metabolism and the
PI3K/AKT/mTOR pathway [21]. The CDH1 gene encodes the cadherin–calcium dependent cell adhesion
protein which regulates the mobility and proliferation of epithelial cells [22], and abnormalities in this
gene are connected with the development of colorectal [22], breast [23], gastric [24] and most likely
also OC [25]. The PAX1 gene is a member of the paired-box transcriptional factor gene family which
regulates proper tissue development and cellular differentiation in embryos [26]. Although its role in
cancer development and progression has not been sufficiently established [27], this gene is aberrantly
hyper-methylated and down-regulated in different types of cancer [28], and is suggested to inhibit
the phosphorylation of multiple kinases, especially after challenges with the EGF and IL6 oncogenic
growth factors [28]. In addition, PAX1 has the ability to activate variable phosphatases, including
DUSP-1, 5, and 6, and to inhibit EGF/MAPK signaling. Its interaction with SET1B increases histone
H3K4 methylation and the DNA demethylation of numerous phosphatase-encoding genes [28].
Finally, changes in DNA methylation were repeatedly noted in OC and these affected the
activity of variable genes, and therefore contributed to the tumorigenesis of variable histotypes.
Furthermore, methylation changes in OC can be prognostic for shorter progression-free survival
(PFS) and chemotherapy resistance [29–31]. Importantly for this study, all four selected genes have
previously been observed to be abnormally methylated in primary OC tumours [25,32–40]. Moreover,
lower mRNA expression in at least one OC histotype in the RASSF1 and PTEN genes [41–43] and
lower CDH1 gene protein expression [44] in OC have been noted. Decreased CDH1 gene expression
also correlated with the methylation levels and all these genes can, therefore, be suitable candidates for
methylation analysis of LB samples from women with OC.
2. Material and Methods
Our sample collection consists of 128 variable types of ovarian tissues and paired plasma samples
from central European caucasian women who underwent surgical excision as part of their treatment.
This includes healthy (mean age 63.83 ± 11.23 years), benign (64.57 ± 16.40 years) and malignant
samples (57.20 ± 11.12 years), and also a few ovarian cancers subsequent to breast cancer (BC-OC)
(59.25 ± 12.74 years) (Table 1). The histological characteristics of the OC samples are summarised by
FIGO staging and subtype in Tables 2 and 3. Personal and gynaecological anamnesis information
was obtained during medical examination and the study was approved by the ethical committee
of Jessenius Faculty of Medicine in Martin Slovakia under number 1933/2016, and the research was
performed in compliance with the Declaration of Helsinki.
Table 1. Number of samples according to the diagnosis.
Tissue Diagnosis Plasma Paired Samples
n % n % n
17 13.3 Control 9 7.0 7
8 6.3 Benign 5 3.9 5
49 38.3 OC 33 25.8 33
4 3.1 BC-OC 3 2.3 3
Note: OC—ovarian cancer; BC-OC—ovarian cancer subsequent to breast cancer.
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Table 2. FIGO classification of OC samples.
Stage n %
1A 5 10.2
1C 3 6.1
1C2 1 2.0
3b 1 2.0
3B 3 6.1
3C 17 34.7
4 7 14.3
4B 5 10.2
No data 7 14.3
Table 3. Histopathological subtypes of OC samples.
Subtype n %
Clear cell 2 4.1
Endometrioid 2 4.1
Mucinous 4 8.2
Serous 16 32.7
Serous papillary 25 51.0
2.1. DNA Isolation and Bisulfite Conversion
Immediately after section, the OT and healthy control tissues were stabilised in RNAlater solution
and kept at −20 ◦C. DNA from tissue and plasma was isolated by DNeasy Blood and Tissue Kit
(Qiagen GmbH, Hilden, Germany) and QIAamp® DSP Virus Kit (Qiagen GmbH, Hilden, Germany).
The concentration was measured by NanodropTM 2000 (Thermo Fisher Inc, Wilmington, DE, USA)
and QuBit (Thermo Fisher Inc, Wilmington, DE, USA). Finally, subsequent bisulfite DNA conversion
was performed by the Epitect Bisulfite Kit (Qiagen Inc., Valencia, CA, USA) and the converted DNA
was stored at −20 ◦C.
2.2. Methylation Analyses
Methylation of bisulfite modified DNA from control tissues, primary tumours and plasma samples
were analysed by pyrosequencing on Pyromark Q96ID (Qiagen GmbH, Hilden, Germany). This is a
very practical and reliable method and it provides quantitave methylation levels relatively quickly.
Sequencing was preceded by PCR amplification by Pyromark PCR Kit® (Qiagen GmbH). The total
reaction volume was 25 µL and comprised 21 µL Pyromark PCR Kit mixture (12.5 µL MasterMix,
2.5 µL CoralLoad Concetrate, 1µL MgCl2, 5µL Q-Solution), 2.5 µL primer pairs, 0.5 µL RNAse free
water and 1 µL bisulfite modified DNA.
The PCR reaction steps were as follows: Activation of polymerase (95 ◦C, 15 min), 45 cycles
(RASSF1) or 50 cycles (PTEN, CDH1, PAX1) of denaturation (94 ◦C, 15 s), annealing (56 ◦C (RASSF1,
PAX1)/62 ◦C (PTEN, CDH1) for 30 s), extension (72 ◦C, 30 s) and final extension at 72 ◦C for 10 min.
The qualitative and quantitative amplicon parameters were subsequently assessed by 1.5% agarose
gel electrophoresis. The amplification process was the same for both DNA from tumorous tissue and
circulating DNA. The PCR amplification primers were modified so that the reverse primer had a
biotinylated 5′ end. This enabled separation of the strand for pyrosequencing analysis.
The PCR product was subsequently used for pyrosequencing. This was first mixed with
streptavidin-coated sepharose beads (GE Healthcare Life Sciences, Chalfont, UK), binding buffer
(Qiagen GmbH) and nuclease free water in a total volume of 80 µL in a Pyromark plate and shaken
for 10 min at 2,500 rpm. The 5′-biotinylated strand for sequencing was immobilised by Pyromark
working station, transferred to a mixture of 0.4 M sequencing primer and binding buffer (Qiagen
GmbH) and incubated for 2 min at 80 ◦C. Finally, the pyrosequencing results were interpreted by
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Pyromark Q96 software version 2.5.8 (Qiagen GmbH). The commercially available CpG methylation
assays® (Qiagen GmbH) were used herein to analyse methylation levels in the following sequences
(Table 4):
Table 4. Analysed sequences of genes RASSF1, PTEN, CDH1 and PAX, and their location in human genome.
Gene Sequence to Analyse Location
RASSF1 5′-GGTAGCGCAGTCGCCGCGGGTCAAGTCGCGGC-3′ 3:50,377,907–50,377,938
PTEN 5′-CGCGAGGCGAGGATAACGAGCTAAGCCTCGGC-3′ 10:89,622,923–89,622,954
CDH1 5′-CGGCAGCGCGCCCTCACCTCTGCCCAGGACGCGGC-3′ 16:68,772,300–68,772,331
PAX1 5′-CGGAATCTGCTAGCTTCGTCGGGCGCGA-3′ 20:21,684,296–21,684,323
2.3. Biostatistical Analyses
Exploratory data analysis was performed by standard summary statistics; the methylation data
was visualised by boxplot overlain with swarmplot; and the heat map provided methylation level mean
values. Data normality was assessed by a quantile-quantile plot with 95% bootstrap confidence band,
and robust ANOVA tested the hypothesis of equality of population methylation medians in the disease
levels. Null hypothesis rejection was followed by the Tukey HSD post-hoc test. The discriminative
ability of the methylation indices and age for various pairs of disease level was then assessed by the
random forest learning algorithm. This quantified the importance of the individual predictors by
minimal depth. The trained random forest discriminative ability was visualised by the ROC curve
based on “out-of-bag” data and the AUC area under the ROC curve and the 95% AUC confidence
interval quantified the discriminative ability of methylation indices and age. Finally, we determined
sample size and performed power analysis for the one-way ANOVA test, assuming balanced design.
All data analysis was performed in R, version 3.5.2 [45].
3. Results
3.1. CpG Sites Methylation Status of the RASSF1, PTEN, CDH1 and PAX1 Gene Regulatory Regions
DNA methylation profiling of 21 CpG sites in four genes, comprising six CpG sites in the RASSF1
gene and five CpG sites in each of the PTEN, CDH1 and PAX1 genes was performed by pyrosequencing
on the four different tissue types—healthy ovarian tissues, benign OT, OC and BC-OC, and also on the
corresponding plasma samples. The mean value, median and standard deviation of each CpG site is
provided in Supplementary Table S1 for tissues and Table S2 for plasma.
Figure 1 shows the methylation value of each CpG site in the tissue (A) and plasma samples (B)
according to diagnosis. The general overview provides information on the hypomethylation of PTEN
CpG sites for all diagnoses and tissue and plasma samples. Greater variability is obvious in the RASSF1
and PAX1 CpG sites, and the highest methylation was detected in the CDH1 CpG sites. The comparison
of tissue samples (Figure 1A) shows the increasing methylation trend from the control sample group to
cancer samples in the RASSF1, CDH1 and PAX1 genes. The statistical comparison of means revealed
the most significant differences between controls and OC samples in two CDH1 and three PAX1 gene
CpG sites and between controls and BC-OC in three PAX1 gene CpG sites. The increasing mean values
for RASSF1 were not statistically significant because of the wide variance in values (detailed statistical
data is contained in Table S1). Figure 1B depicts variability in the plasma group methylation values,
with no visible linear trends detected between the diagnostic groups. Finally, the statistically significant
higher methylation levels were detected in OCs in four CDH1 gene CpG sites compared to controls,
and all detailed statistical data is listed in Table S2.
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Figure 1. Heat map of each CpG site methylation values in tissue (A) and plasma samples (B) according
to diagnosis. OC—ovarian cancer; BC-OC—ovarian cancer subsequent to breast cancer.
3.2. DNA Methylation Indices of the RASSF1, PTEN, CDH1 and PAX1 Gene Regulatory Regions
The methylation index (MI) is the mean percentage of methylation across all CpG sites analysed
per gene, and that was calculated for each ge e and di nostic group in the tis ue and plasma sampl s.
The MI values of e ch diagnostic group ar depicted by the heat maps in Figure 2A for tissue and 2B for
plasma. Although PTEN g ne methylation indices were very low, they were statistically significantly
different between benign t mours (3.90 ± 4.10) and malignant OC (3.00 ± 2.60) in the tissue samples.
No statistically significan differences were determined in RASSF1 MI between diagnostic groups in
either the tissue or plasma s mples. In the tissue samples, the CDH1 an PAX1 gene methylation
indices had increasi g tendency toward OC, with statistically significant difference between controls
(24.22 ± 6.93 for CDH1 and 5.73 ± 2.19 for PAX1) and OCs (39.06 ± 18.78 and 13.55 ± 10.65) in
both g es, and also between c ntrols (5.73 ± 2.19) and BC-OC samples (22.90 ± 13.56) in the PAX1
gene. In the plasma s mple , there was ly one statistically significant differ nce between controls
(22.25 ± 14.13) and OC samples (46.42 ± 20.91), in the CDH1 gene. Detailed data is provided in
Supplementary Table S3.
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3.3. Methylation Pattern by FIGO Staging and Histological Type
The methylation levels of all CpG sites revealed little statistically significant differences between the
compared FIGO stages (data not shown) and the MI data pattern is depicted in Table 5. Two following
trends were observed: The RASSF1 and PAX1 methylation indices decreased with disease severity
increase, and the CDH1 and PTEN values had increasing tendency, thus followiing the stages. Statistical
comparison of the mean values revealed significant differences only in the PTEN gene and between
stages I and II, and stages I and IV in the PTEN gene.
Table 5. MI averages of CpG sites in regulatory regions of the RASSF1, PTEN, CDH1 and PAX1 genes
in tissue samples according to FIGO stage.
Stage I (n = 9) Stage II (n = 21) Stage IV (n = 12)
p-Value
Mean Median SD Mean Median SD Mean Median SD
MI_RASSF1 19.24 5.33 20.46 17.24 7.50 19.80 8.01 6.83 3.95 ns
MI_PTEN 2.09 2.00 1.37 3.47 3.60 1.49 3.63 3.60 1.37 a, b
MI_CDH1 32.89 29.00 16.81 39.98 30.50 20.72 48.38 44.25 17.76 ns
MI_PAX1 17.11 13.60 17.36 11.56 10.40 5.42 10.98 8.50 6.28 ns
Note: Due to number of cases in each category, we created only three groups, based on the FIGO stage numbers (for
example 1A, 1B and 1C were merged into stage I); ns—non significant difference between groups; a—statistically
significant difference (p < 0.05) between FIGO I and II; b—between FIGO I and IV.
Comparison of the methylation levels and indices between histological subtypes revealed only
sporadic differences and indicated possible uniform methylation of the studied genes in this OC group.
3.4. Comparison of Methylation Indices in Tissue and Plasma Paired Samples
The MI values of paired tissue and plasma samples were compared to assess if the plasma
methylation status reflects those observed in the primary tumours. Figure 4 shows similarities and
differences in the methylation indices of all RASSF1, PTEN, CDH1 and PAX1 gene paired samples,
and statistical analysis determined significant plasma and tissue correlation only in the CDH1 and
PAX1 genes. The correlation coefficient of CDH1 MI was negative in controls (r = −0.812, p = 0.05),
but positive in benign samples (r = 0.886, p = 0.019) and OC samples (r = 0.428, p = 0.015). However,
strong correlation was established between plasma and tissue in all PAX1 CpG sites and between PAX1
methylation indices, but only in the OC pairs (r = 0.771, p < 0.001).
The results for sample size determination, including the effect size and the number of observations
in each group needed to maintain 80% power level, are included in Supplementary Table S4 for tissue
samples and Table S5 for plasma samples.
3.5. Evaluation of the Diagnostic Predictive Model Using ROC Analyses
Finally, we used the random forest algorithm with ROC analysis to evaluate if the studied
methylation indices combined with age could significantly distinguish between diagnoses. Table 6
provides the AUC values with 95% confidence intervals for tandem discriminations. The “Important
variable” column denotes the most relevant variables based on importance measured by minimal
graph depth. The best AUC values were obtained in the model which discriminate between controls
and OC samples based on both the MI of the four genes in tissues (AUC = 0.932) and in plasma
(AUC = 0.822). The first “tissue” model had perfect sensitivity (98%), but specificity was weak (34%).
The same was observed in the “plasma” model, with 91% sensitivity and 56% specificity. Based on
the AUC values and 95% CI, these models indicate strong predictive power, and can, therefore, be
considered for diagnostic discrimination clinically.
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4. Discussion
OC is one of the most lethal cancerous diseases, and despite the progress in surgical techniques,
better management, advanced chemotherapy and targeted therapy, the OC patient survival rate is
still very low and almost 70% of all patients are diagnosed in advanced stages. This is mainly due to
the lack of early symptoms in this disease [8]. Early OC screening approaches have been traditionally
based on serum CA-125 concentration and trans-vaginal ultrasound, but both these methods lack
sufficient sensitivity and specificity [46,47]. Therefore, non-invasive biomarkers able to predict early
OC presence and monitor response to treatment and cancer progression are imperative. However,
those with sufficient predictive power are still lacking and most possible candidates require further
investigation [46,48,49]. Moreover, further use of the tumour markers is crucial in all gynaecological
cancerous diseases [50–52]. For example, CTC, ctDNA, cfmiRNAs and released exosome vesicles can
be analysed in the assessment of molecular markers. This assessment can be performed by a variety of
methods, from basic PCR modifications to advanced multi-parallel sequencing approaches [10].
Herein, we focused on the epigenetic impact on OC formation by analysing the methylation
levels of the RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes’ regulatory sequences. We
compared the methylation status of normal tissue, benign, OC and BC-OC samples. We then assessed
the methylation levels in these genes in the corresponding plasma samples in order to estimate their
potential for LB utilisation. Finally, we compared the methylation patterns in the tissue samples and
the paired plasma samples to assess if these patterns were markedly different.
Previously published articles reported the importance of some genes’ plasma methylation status
in OC management. For example, the C2 CD4 D, WNT6 and COL23 A1 genes’ methylation status
is not only significantly altered in OC patients’ ctDNA, but different responses to platinum-based
therapy can also be associated with their methylation levels [53]. Moreover, Giannopolou et al. [54]
discovered altered ESR1 gene methylation levels in the ctDNA samples of high-grade serous OC
patients, and these abnormalities are very similar to those in primary tumours [54].
The most notable methylation changes in solid OT are in the BRCA1 [29,55], OPCML [56],
HOXA9 [33] and P16 INK4α genes [57]. BRCA1 is methylated in up to 30% [29,55] of these tumours
and OPCML is methylated in over 80% of OT [56]. Interestingly, RASSF1 A is the major RASSF1
gene isoform and this has been repeatedly analysed for methylation changes in both OC tissues and
plasma samples. For example, de Caceres et al. [32] noted methylation of the RASSF1 A gene in 50% of
primary OT and detected an identical pattern of gene hyper-methylation in 41 of 50 (82%) matched
plasma DNA. In addition, hyper-methylation of this gene was recorded in all OC histological types,
grades and stages. Wu et al. [33] reported very similar results in solid tissues, with hyper-methylation
in 49% of patients with various OC types and grades. In contrast, Agathanggelou et al. [58] found
hyper-methylation in only 10% of solid OT.
Methylation changes in the RASSF1 A promoter have already been analysed for utilization in
non-invasive differentiation of epithelial ovarian carcinoma from healthy controls. For example,
90% sensitivity and 86% specificity for cancer detection was determined when methylation levels of
the RASSF1 A, EP300 and CALCA genes were used in combination [59]. In addition, the multiplex
methylation specific PCR (MSP) assay of seven different genes, including RASSF1 A, achieved 85.3%
sensitivity and 90.5% specificity in differentiating epithelial OC from healthy controls in serum
samples [60]. Variable RASSF1 A methylation has also been noted in tissue samples of serous and
non-serous types and benign tumours [61].
Herein, the RASSF1 A MI differed in all four tissue types. It was higher in primary malignant
tumours (17.98 ± 19.73) than in healthy tissue (9.50 ± 6.21), but the opposite was found in plasma
ctDNA. Here, the controls have higher MI (11.74 ± 8.34) compared to malignant samples (8.93 ± 4.54).
However, no statistically significant differences were established between particular CpGs or mean
methylation indices. Importantly, although these differences proved insignificant, they can indicate
wide methylation changes in RASSF1 gene regulating sequences and the important role of methylation
in silencing this gene in OC development as is generally suggested [29].
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Although the methylation status of the PTEN CpG sites and methylation indices was generally low
and homogenous, there were statistically significant differences between benign and malignant lesions.
The decreasing tendency in methylation indices was observed in both tissue and plasma samples,
but comparison between FIGO stages revealed a statistically significant increase in methylation indices
only in the higher FIGO stages. This theoretically indicates its important role in cancer formation and
spread. Herein, however, we compared only the main FIGO categories where subtypes were merged
in one main category, because of the small sample size. In addition, the differences between the FIGO
stages were not only low, but the methylation indices themselves also had low values. This leads to
debate if such small increases in methylation levels can contribute to tumour progression from stage I
to stage IV. This is especially pertinent when previous very low PTEN methylation levels have occurred
without differences in OC FIGO stages [34].
Yang et al. [34] and Zuberi et al. [35] recorded relatively low methylation values in the PTEN
gene with higher methylation in only 16% and 8.2% of the samples, respectively. Schondorf et al. [62]
suggested that PTEN methylation should have only a subordinate role in OC progression and only the
one study by Qi et al. [36] reported relatively higher methylation levels of this gene in OC. Overall,
the low and homogeneous PTEN methylation concord with the most of previous studies, and the
small increase in methylation should not reflect progression from stage I to stage IV, though statistical
significance is established between the FIGO stages. Our results also indicate the potential effect
of PTEN methylation changes in benign lesion formation. That suggests that further analysis of
the methylation changes will be beneficial, because there is no rule that benign lesions must be less
methylated than malignant lesions, and different mechanisms can lead to abnormal methylation in
benign and malignant tumours [63].
In comparison to RASSF1 and PTEN, the PAX1 gene had greater variation in methylation levels with
statistically significant differences between controls, OC and BC-OC. There was also wide variability
in particular CpG islands, especially in the control and malignant samples. This gene’s methylation
provides a potential biomarker for cervical cancer screening [64–66], but important methylation
changes in this gene were also noted in OC. In particular, Su et al. [37] reported 50% PAX1 methylation
rates in OC, but only 14.3% in borderline tumours and 4% in benign, and Hassan et al. [38] found
hyper-methylation in 50%, 50%, 46.6% and 78% of patients depending on the FIGO stage of epithelial
OC. In addition, the authors associated methylation levels with the presence of HPV16/18 infection.
Neither of these studies can be quantified in the same manner as our quantitative pyrosequencing
results because they used MSP in their assessment, but the significant differences we achieved between
healthy tissues and cancer samples can be interpreted quite similarly—that dynamic methylation
changes indicating OC’s presence occur in the aforementioned gene’s regulation sequences. Although
our results established no statistical significance, they can certainly help move the debate on how this
gene’s methylation changes affect the formation of benign lesion because the methylation levels were
as high they are in cancerous tissues.
Finally, the CDH1 gene had statistically significant variability in methylation levels between
control and malignant tissue samples, and this agrees with previous analyses [25,39,40]. Importantly,
this gene also had statistically significant plasma samples differences in both mean methylation levels
and those of particular CpG dinucleotides in both healthy and cancerous groups. Therefore, the CDH1
gene could be considered a very promising candidate for non-invasive LB-based diagnosis of malignant
OC, but its potential for non-invasive investigation of benign tumour presence requires further analysis.
It is important to realize that even non-significant, but observable differences in plasma samples
methylation levels were revealed also in the RASSF1, PTEN and PAX1 genes, and this could inspire
additional analyses of these genes. The large deviation in the final methylation levels of these genes
was very likely the main obstacle to achieving statistical significance. However, larger sample collection
could help to solve this problem.
One of the issues in the analysis of plasma samples is the lack of definition and accepted consensus
if changes, including those in ctDNA methylation, remain exactly the same as in the primary tumours
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that released them. While some authors consider that the aberrant patterns remain identical to those
in the primary tumour [53,67–72], others support diverse patterns [73–75]. Herein, we conform to
similarity because of the strong correlations between tissue and plasma samples in the CDH1 and PAX1
genes, and also in several RASSF1 and PTEN gene samples. Discrepancies in tissue and plasma sample
methylation levels could have also occurred herein because circulating cfDNA of cancer patients
contains a mixture of DNA from both normal and cancerous cells. The ratio of ctDNA in the entire
cfDNA fraction can vary because this depends on several tumour parameters [76]. Our methodology
cannot estimate how plasma sample results are affected by the presence of non-tumorous cfDNA
elements, and we cannot exclude that this is responsible for the variability obtained in the results.
Although the ctDNA ratio is generally quite low it can vary widely, and some estimations of ctDNA
abundance reach 90% [76,77]. Importantly, it has been demonstrated that the concentration of all
circulating free molecules, and not only ctDNA, is associated with a tumour volume which gives
shorter overall survival (OS) for OC patients [78].
Previously performed LB-based methylation analyses assessing the methylation pattern in
OCs using non-NGS approaches have provided very interesting results. Those include (1)
Teschendorff et al. [79], when they used a methylation-array based study and observed significant
differences in the blood of healthy and cancerous patients, and (2) Flanagan et al. [80], who utilised
the pyrosequencing approach and determined significant correlation of SFN gene methylation with
PFS. In addition, their subsequent study [81] noted specific CpGs’ alterations in blood DNA following
relapse from platinum-based chemotherapy, and their results proved an independent significant
association with survival. Moreover, both pyrosequencing and MSP have previously been used to
assess methylation abnormalities in plasma samples from different cancer types, and some of these
achieved significant results assessing the profiles of all circulating DNAs, not only ctDNA [82–86].
Therefore, even methodology which is unable to distinguish ctDNAs in the whole cfDNA fraction can
be useful in assessing disease characteristics from LB samples. We also incline toward the consensus
that changes in primary tumours should remain preserved in ctDNA elements and the changes noted
in primary tumours could then be used as inspiration for initiating further experiments utilising LB
samples. Therefore, known abnormalities in primary tumours can be very helpful because these can
be searched and analysed in LB samples.
OC is widely recognised as a very heterogeneous group and it should, therefore, be important to
analyse and interpret the results of each histotype. However, the rarity of some morphological subtypes
causes study limitations, and the small numbers in some histotypes herein prevented performance
of statistical analysis. Only the serous and serous papillary histotypes were sufficient for analysis,
and these recorded no significant differences in their methylation levels and were even almost identical.
While studies have confirmed that some differences are typical for all OC histotypes [25,32–34,56], it
cannot be ignored that unintentional variance in our results is due to the heterogeneity of our collection
and also the impossibility of separating and analysing particular histotypes.
The effect size and the number of observations in each group required to maintain 80% power
were assessed by power analysis, and these are listed in supplementary Tables S4 and S5. Herein,
the number of malignant tissues was mostly sufficient, but we occasionally noted a lack in the number
of healthy controls and the number of benign lesions was quite often lower than proposed. Therefore,
although the power analysis results may limit our study through having a sample size insufficient to
assess methylation levels in all CpGs with sufficient statistical power, it can help design the same or
similar experiments. The highest number of required observations, excluding three PTEN gene CpG
sites in plasma samples, was 64, and it is quite possible to collect at least that number of samples for
future analysis.
It has been noted that there are generally higher cfDNA levels in malignant OC patients than in
healthy patients and in those with benign lesions [87,88]. The cfDNA levels are also lower in FIGO I–II
stages than in the III–IV stages [78]. Although we assessed only four genes’ methylation indices and
not the entire cfDNA levels, and therefore cannot directly associate these parameters, analysis of the
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relationship between methylation changes, tumour stage and general cfDNA levels could most likely
provide clinical implications. It would be beneficial, therefore, to design further studies which assess
these relationships.
The cfDNA characteristics can also vary depending on age [89] and the presence of concomitant
disease [90]. Furthermore, it is presumed that length of cfDNA fragments correlates with shorter PFS,
and also OS [91]. Unfortunately, we can neither confirm nor preclude that our results are affected by
other clinical attributes, such as the presence or absence of other patient disease. However, further
studies should establish associations between a wide variety of clinical parameters, methylation and
also cfDNA levels, as previously suggested.
Herein we evaluated the predictive performance of the combined model of DNA methylation
signature (MI of the genes) and the age (in years) using ROC analyses computed by the random forest
algorithm. We ran six models separated for sample type. The model which discriminated between
control and OC samples had the highest predictive power—at 0.932 AUC in tissue samples and 0.822 in
plasma. This initially appeared a perfect model with high sensitivity and clinical application potential,
but 34% specificity for tissue samples and 56% for plasma samples means that too many healthy
women would be incorrectly classified as cancer patients. The most likely reason for these results was
the small number of controls, and this could have affected statistical analyses and hindered efforts to
ensure a strong statistical model. Adequate AUC values were obtained in the model discriminating
control samples and benign samples (tissue: AUC = 0.729, 85.7% sensitivity and 83.3% specificity;
plasma: AUC = 0.778, 100% sensitivity and 66.7% specificity). Our last discrimination model of benign
and OC samples had insufficient classifiers. In these models, PAX1 MI and CDH1 MI were selected
as the most important variables for tissue and plasma respectively, and this indicates the previously
described results about tissue and plasma non-conformity. Although these analyses promised a
high-quality classifier, other possibilities should now be also considered. The most important would
be the inclusion of additional control samples, as this would provide more accurate specificity. It is
also worth considering the inclusion of more variables in the model, such as gynaecological anamnesis,
life style risk factors and also CA-125 or other novel biomarkers with the potential to detect serous OC
at earlier stages and predict patient survival prognosis [92–94]. Although this is beyond the scope
of this pilot project, it should provide inspiration for further analyses focused on specific variables
identified by a multinomial approach and offer personalised tailored therapy. Because of the great
variability in this disease, the management of OC should be individualized, and performance status of
the patient should be considered. This is best reflected in necessity for different treatment option for
younger and older women [95,96]. In addition, future individual OC treatment should also be based
on different patient physiological and health parameters.
In conclusion, our study confirmed higher methylation levels in several CpG sites and also higher
methylation index in RASSF1 A, PAX1 and CDH1 genes in OC tissues compared to control tissues.
However, no statistical significance was noted in the RASSF1 gene because of high variance. Statistically
significant higher MI and CpG sites methylation levels were detected in plasma samples only in the
CDH1 gene. PTEN gene was slightly and homogenously methylated. In addition, we recorded similar
methylation patterns with strong correlations in the CDH1 and PAX1 genes in OC plasma and tissue,
and the results suggest that the CDH1 gene is a prospective candidate for non-invasive, LB-based
differentiation in OC. Our diagnostic discrimination model combined the methylation indices of all four
genes with age, and this revealed the highest AUC 0.932 predictive power in the model, comparing OC
subjects with controls. Finally, it will prove highly beneficial to employ as many LB-based approaches
as possible in cancer detection and treatment, especially in OC, which has such high risk and generally
delayed diagnosis. LB is capable of providing early OC diagnosis which can help decrease the global
expense of fighting this disease, but most importantly it can save lives, or at least prolong them with
greater life quality for the thousands of women affected by this lethal cancer.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/17/
4119/s1.
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